IVI. A. Voznuk

I. A. Voznuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


I. A. Voznuk has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment of the efficacy of Cytoflavin in the acute phase of ischemic stroke: a systematic review and meta-analysis

    by A.M. Alasheev, T.V. Kharitonova, N.A. Shamalov, S.N. Yanishevskiy, D.R. Khasanova, N.A. Marskaya, I.A. Voznuk

    Objective. To evaluate the effectiveness of Cytoflavin in conjunction with standard therapy compared to standard therapy alone in patients presenting during the acute phase of ischemic stroke (IS). Material and methods. A systematic literature review and meta-analysis were conducted to assess the efficacy of Cytoflavin (containing inosine, nicotinamide, riboflavin, and succinic acid; STPF POLYSAN, Ltd., Russia) in adult patients diagnosed with IS. The analysis encompassed both randomized and non-randomized controlled trials, assessing outcomes such as hospital mortality, neurological deficit (measured using the National Institutes of Health Stroke Scale, NIHSS), and functional outcomes (assessed using the modified Rankin Scale and Barthel Index). Results. The incorporation of Cytoflavin into standard treatment protocols was associated with a statistically significant reduction in mortality rates when compared to standard therapy alone (hazard ratio [HR]=0.53; 95% confidence interval [CI] 0.37; 0.76, p<0.001). Furthermore, there was a notable improvement in the regression of neurological deficits during the acute phase of IS, as evidenced by higher NIHSS scores and better functional outcomes (Barthel Index) in patients receiving Cytoflavin. Conclusion. The findings from this systematic review and meta-analysis indicate that the addition of Cytoflavin to standard therapy for ischemic stroke is associated with more favorable clinical outcomes, including decreased mortality, diminished neurological impairment, and improved functional outcomes at the end of the IS acute phase. It is imperative to consider the high heterogeneity in the functional scales data across studies when interpreting these effects.

  • Open Access

    Fortelyzin in the treatment of acute ischemic stroke due to basilar-artery occlusion: data from the observational study FORPI registry

    by N. A. Shamalov, M. Yu. Martynov, N. A. Marskaya, D. R. Khasanova, E. B. Yarovaya, I. A. Voznuk, L. V. Timchenko, A. M. Alasheev, N. V. Khalo, M. D. Bogatyreva, et al.

    The approach to reperfusion therapy for acute ischemic stroke (AIS) in cases of basilar artery occlusion (BAO) remains a matter of debate.    Objective:  to assess the safety and efficacy of Fortelyzin in patients with BAO in real-world clinical practice, based on data from the FORPI registry.   Material and methods.  The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with ischaemic stroke. An analysis was conducted of the safety and efficacy of Fortelyzin in a group of patients with basilar artery occlusion who underwent intravenous thrombolytic therapy (IVT) and bridging therapy. The safety endpoint was the incidence of symptomatic intracranial haemorrhage (SICH) as defined by ECASS III and SITS-MOST, as well as all-cause mortality at 90 days. The efficacy endpoint was defined as good functional recovery, defined as a score of 0–2 on the modified Rankin Scale (MRS) at 90 days.    Results. This analysis included 1910 patients who underwent IVT and 53 patients who underwent bridging therapy. The median National Institutes of Health Stroke Scale (NIHSS) scores at admission were 9 and 12 points, respectively (p = 0.01). SICH incidence (ECASS III criteria) was significantly higher in the bridging therapy group compared to IVT group (6 % vs 1 %, p = 0.01). All-cause mortality at day 90 did not differ significantly between the groups (9 % and 7 %, respectively, p = 0.52). Good functional recovery at day 90 was achieved by 69 % of patients in the IVT group and 60 % of patients in the bridging therapy group (p = 0.31).    Conclusion. The use of Fortelyzin in AIS patients with BAO may be considered an effective and safe form of reperfusion therapy, as well as a component of bridging therapy aimed at increasing the number of favorable functional outcomes.

  • Open Access

    Fortelyzin in the treatment of minor acute ischemic stroke according to a subanalysis of the observational study FORPI registry

    by N. A. Shamalov, M. Yu. Martynov, N. A. Marskaya, D. R. Khasanova, E. B. Yarovaya, I. A. Voznuk, L. V. Timchenko, A. M. Alasheev, N. V. Khalo, M. D. Bogatyreva, et al.

    The question of whether intravenous thrombolytic therapy (ITT) is appropriate for patients with a minor stroke (NIHSS score < 5) remains a matter of debate. Fortelysin is a thrombolytic agent used to treat ischemic stroke.    Objective:  to assess the safety and efficacy of Fortelyzin in patients who have suffered a minor stroke in real-world clinical practice, based on data from a subanalysis of the FORPI registry.    Material and methods.  The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with acute ischemic stroke. We analyzed the safety and efficacy of Fortelyzin in a group of patients with minor stroke characterized by an NIHSS < 5. Safety outcomes were the number of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality at day 90. The efficacy outcome was a functional independence, defined by modified Rankin scale (mRS) score of 0–2 points at day 90.    Results.  The analysis included 836 patients with an NIHSS < 5 points. The median age was 64 [56; 72] years, and the median NIHSS score at admission was 4 [3; 4] points. SICH according to ECASS III definition was observed in three patients of 836 (0.4 %), and according to SITS-MOST definition, in four patients of 836 (0.5 %). All-cause mortality at day 90 was 2.2 % (18/836). The proportion of patients with functional independence (mSR of 0–2 points) at day 90 reached in 88 % (737/836) of patients.    Conclusion. The FORPI registry provides compelling evidence that early intensive rehabilitation using Fortelyzin is characterised by a high level of safety and efficacy in patients who have suffered a minor stroke.

  • Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry

    by N.A. Shamalov, M.YU. Martynov, N.A. Marskaya, D.R. Khasanova, E.B. Yarovaya, I.A. Voznuk, L.V. Timchenko, A.M. Alasheev, N.V. Khalo, M D Bogatyreva, et al.

    Objective. The aim of this study was to evaluate the safety and efficacy of Fortelyzin in patients ≥80 years with ischemic stroke (IS) in real-world clinical practice using data from the FORPI registry. Material and Methods. Fortelyzin (INN/chemical name — a recombinant protein containing the amino acid sequence of staphylokinase, SuperGene LLC, Moscow, Russia) is a thrombolytic used for acute IS treatment within the first 4.5 hours of symptom onset. The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with IS. We analyzed the safety and efficacy outcomes in patients ≥80 years compared with patients <80 years. Safety outcomes included the incidence of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by an mRS score of 0—2 on day 90. Results. 2649 (15%) patients were ≥80 years, and 14 987 (85%) patients were <80 years. The median age in the group of patients ≥80 years was 83 (82—86) years. Patients ≥80 years were characterized by a more complicated medical history and a higher median of NIHSS and mRS score. The sICH rate according to ECASS III definition in patients ≥80 years old was 4.0%, in patients <80 years old — 1.7% (OR 2.42 (1.90—3.07), p<0.001), according to SITS-MOST definition — 3.2% and 1.6%, respectively (OR 2.03 (1.56—2.61), p<0.001); in-hospital all-cause mortality was 17% and 7% (OR 2.76 (2.44—3.11, p<0.001), all-cause mortality on day 90 was 19% and 7% (OR 3.00 (2.67—3.37, p<0.001), respectively. Good functional recovery (mRS 0—2 score) on day 90 was achieved in 43% of patients ≥80 years and 64% in patients <80 years of age (OR 0.42 (0.38—0.46, p<0.001)). Conclusion. FORPI study showed that although the risk of sICH with Fortelyzin is higher in patients ≥80 years than in patients <80 years, it remains low, suggesting that thrombolytic therapy is safe and necessary in these patients.


  • Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry

    by N.A. Shamalov, M.YU. Martynov, E.I. Gusev, D.R. Khasanova, V.N. Nesterova, N.A. Marskaya, E.B. Yarovaya, Zh.YU. Chefranova, I.A. Voznuk, T.V. Kharitonova, et al.

    Objective. To evaluate the safety and efficacy of Fortelyzin during bridging therapy (thrombolysis followed by thrombectomy) in real-world clinical practice using data from the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with acute ischemic stroke. In this article we analyzed the safety and efficacy of Fortelyzin in patients undergoing thrombolysis followed by thrombectomy. The safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by mRS score of 0—2 on day 90. Results. The analysis included 1116 patients undergoing thrombolysis followed by thrombectomy who were enrolled in a registry at 120 medical cites in 55 regions of the Russian Federation. The median patient age was 69 (61—77) years. The median NIHSS score at admission was 15 (12—19) points. The sICH rate according to ECASS III was 13% (144/1116), and according to SITS-MOST was 9% (98/1116). In hospital mortality rate was 27% (301/1116 patients). All-cause mortality on day 90 was 29% (322/1116 patients). Good functional outcome (mRS 0—2) on day 90 was achieved in 38% (422/1116) of patients. Conclusion. This study demonstrates the safety and efficacy of Fortelizin in bridging therapy of acute ischemic stroke in real-world clinical practice.


  • Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry

    by N.A. Shamalov, M.YU. Martynov, E.I. Gusev, N.A. Marskaya, D.R. Khasanova, E.B. Yarovaya, Z.YU. Chefranova, I.A. Voznuk, A.M. Alasheev, M.V. Sutormin, et al.

    Objective. To evaluate the safety and efficacy of Fortelyzin thrombolytic drug (non-immunogenic staphylokinase) in AIS patients in an «extended» therapeutic window from 4.5 to 24 h from symptoms’ onset based on data from the FORPI registry. Material and methods. Functional outcomes and the risk of intracranial hemorrhage after thrombolytic therapy (TLT) for acute ischemic stroke (AIS) are known to be directly dependent on the treatment time initiation. Although the most safe and effective time for TLT is the first 4.5 h from symptoms’ onset, a significant proportion of patients are hospitalized beyond this time window. The objective of this study is The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in AIS patients in real-world clinical practice. A comparative analysis of safety and efficacy outcomes was conducted in groups of patients who received TLT in the first 4.5 h after symptom onset and beyond 4.5 h time window. The safety endpoints were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST criteria, as well as all-cause mortality at day 90. The efficacy endpoint was good functional recovery, defined by a modified Rankin Scale (mRS) of 0—2 score at day 90. Results. The analysis included 17.636 patients with TLT performed in the first 4.5 h after symptom onset and 358 patients with TLT performed beyond 4.5 h time window (up to 24 hours). In the group of patients with TLT performed in the interval of 4.5—24 hours, there were statistically significantly fewer people over 80 years old (8% vs 16%, p=0.001), and a lower median age (66 vs 68 years, p=0.002) compared with the group of TLT within 4.5 hours. The NIHSS median was slightly higher in the group of patients with TLT performed beyond 4.5 h time window (11 (8—16) vs 11 (8—15), p=0.036). The incidence of sICH (ECASS III) within 4.5 h was 2% compared with 2.5% beyond 4.5 h time window (p=0.454). All-cause mortality at 90 days in the main population was 9%, which is comparable with the mortality rate in the 4.5—24 h group — 7% (p=0.160). Good functional recovery (mSR 0—2) at day 90 was achieved in 61% of patients in the group who received TLT within 4.5 h, compared with 65% of patients who received TLT beyond 4.5 h time window (p=0.227). Conclusion. FORPI registry demonstrates similar data on the safety and efficacy of TLT with Fortelyzin in AIS patients both within 4.5 hours and beyond 4.5 hours from symptoms’ onset.


  • Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry

    by N A Shamalov, M Yu Martynov, E I Gusev, N A Marskaya, D R Khasanova, E B Yarovaya, Zh Yu Chefranova, I A Voznuk, A M Alasheev, S E Chuprina, et al.

    Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.


  • Posterior reversible encephalopathy syndrome in children with hematological diseases

    by N.V. Bronina, I.O. Shchederkina, A.YU. Polushin, E.V. Seliverstova, Y.B. Skiba, K.I. Kirgizov, G.O. Bronin, I.A. Voznyuk

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка факторов риска (ФР) и тяжести течения синдрома задней обратимой энцефалопатии (PRES) у детей с заболеваниями системы крови. МАТЕРИАЛ И МЕТОДЫ Проанализированы случаи PRES у детей с заболеваниями системы крови на этапах полихимиотерапии (ПХТ) и после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). Оцениваемые ФР: артериальная гипертензия, терапия глюкокортикостероидами (ГКС), ПХТ/иммуносупрессивная терапия (ИСТ), инфекционный процесс, нарушение почечной функции. РЕЗУЛЬТАТЫ В анализ включено 35 случаев PRES у 32 детей (8 — после алло-ТГСК, 27 — на этапах ПХТ). В большинстве (94,3%) наблюдений PRES развился у пациентов с двумя ФР и более. Наиболее значимыми ФР были: повышение артериального давления (88,6%), проводимая ПХТ и ИСТ (82,8%), терапия ГКС (71,4%). Течение инфекционного процесса и снижение почечной функции играют меньшую роль в развитии PRES (31,4 и 14%). В дебюте PRES отмечались судороги (94,3%), нарушение уровня сознания (28,6%), головная боль, нарушение зрения и боли в животе (20%). В большинстве (91,4%) наблюдений — 2-я и 3-я степени тяжести по шкале оценки токсичности Common Terminology Criteria for Adverse Events (CTCAE 5.0). По данным магнитно-резонансной томографии (МРТ) головного мозга (ГМ), вазогенный отек выявлялся в теменных (88,6%), затылочных (74,3%), лобных (40%) долях и мозжечке (22,9%) чаще, чем цитотоксический отек (p=0,03). Цитотоксический отек был визуализирован в таламусе и базальных ганглиях (22,9%) чаще, чем в других отделах ГМ (pp<0,05).


  • Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type

    by S.A. Boitsov, M.A. Piradov, M.M. Tanashyan, I.A. Voznyuk, M.V. Yezhov, E.V. Oshchepkova, I.V. Sergienko, N.A. Shamalov, Ya.B. Skiba, S.N. Yanishevskiy

    Ischemic stroke (IS) is one of the main causes of death and permanent disability. Reducing the burden of stroke is possible if effective preventive measures are provided. The possibilities of correcting lipid metabolism as an important measure aimed at preventing IS are analyzed.